CRI market research report

UK Dry Eye Market Report Forecast till 2027

$4950 – $7250

The UK dry eye market is anticipated to register a significant CAGR of 3.93% to surpass USD 106.19 Million by the end of 2027.

SKU: MRFR220309 Category: Tag:

Description

UK dry eye market Forecast till 2027

Market Overview
The UK dry eye market is anticipated to register a significant CAGR of 3.93% to surpass USD 106.19 Million by the end of 2027. Dry eye is an ocular disorder caused by the lack of tear fluid to lubricate the eyes. This can be an indicator of either low production of tears or rapid evaporation of the film of tears on the surface of the eyes, which can be brought about by several conditions.

The growth of the UK dry eye market can be attributed to the increasing number of the geriatric population prone to various eye disorders such as dry eye and the upsurge in the prevalence of disease conditions such as diabetes that affect the functioning of the eyes.

A promising number of pipeline drugs for dry eye disease (DED) is another key factor driving the market growth. The aging population in the country has led to an increase in the prevalence of overall dry eye disease in the country.

The growth of the UK dry eye market is expected to be driven by the increasing aging population prone to various eye disorders, the rising prevalence of dry eye diseases, and novel treatment methods available for eye disorders.

In addition, the promising treatment of Dry Eye Diseases (DED) and the rising number of laser surgeries are propelling the market growth in the UK. However, the dearth of skilled ophthalmologists, adverse reactions of products, and lack of awareness related to the disease are expected to restrict the market growth. However, the lack of awareness about the disease, self-medication by patients suffering from DED, and adverse effects from dry eye products are a few factors limiting the market growth of the UK dry eye market.

Furthermore, market players in the country are involved in new product launches, geography expansion, and acquisitions.

For instance, in November 2020, Santen UK company launched an artificial tear product, and an online resource platform, my eye care. health, to tackle the UK’s growing burden of dry eye disease. Such product innovation by the company focused on the treatment of DED by the players in the country is propelling the market growth of the UK dry eye market.

Market Segmentation
The UK dry eye market is segmented into products, drugs, end-user, and regions. Based on product the market is further classified into Liquid Drops, Gel, Liquid Wipes, and Eye Ointment. The drug segment is classified into Artificial lubricant eye drops, anti-inflammatory drugs, and autologous serum eye drops. The end-user segment divides the market into Hospital Pharmacies, Retail Pharmacies, and others.

Major Players
The major players operating in the dry eye market are Otsuka pharmaceutical Co Ltd, Teva Pharmaceutical Industries Ltd, Johnson & Johnson Services Inc, Novartis AG, I-MED Pharma, Lenstore, and Vision Direct.

Additional information

Publisher

Geography Covered

Date Published

Pages

Format

Table of Contents

TABLE OF CONTENT 1 EXECUTIVE SUMMARY 2 MARKET INTRODUCTION 2.1 DEFINITION 2.2 SCOPE OF THE STUDY 2.3 RESEARCH OBJECTIVE 2.4 MARKET STRUCTURE 2.5 ASSUMPTIONS & LIMITATIONS 3 RESEARCH METHODOLOGY 3.1 DATA MINING 3.2 SECONDARY RESEARCH 3.3 PRIMARY RESEARCH 3.4 BREAKDOWN OF PRIMARY RESPONDENTS 3.5 FORECASTING TECHNIQUES 3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 3.6.1 BOTTOM-UP APPROACH 3.6.2 TOP-DOWN APPROACH 3.7 DATA TRIANGULATION 3.8 VALIDATION 4 MARKET DYNAMICS 4.1 OVERVIEW 4.2 DRIVERS 4.2.1 RISING PREVALENCE OF DRY EYE DISEASE 4.2.2 PROMISING PIPELINE DRUGS FOR DRY EYE DISEASE 4.2.3 TECHNOLOGICAL ADVANCEMENTS AND EMERGENCE OF NOVEL DIAGNOSTIC TOOLS 4.3 RESTRAINTS 4.3.1 LIMITED AWARENESS RELATED TO DRY EYE DISEASE 4.3.2 ADVERSE REACTION FROM DRY EYE PRODUCTS AND NO PROPER CURE AVAILABLE 4.4 OPPORTUNITY 4.4.1 COLLABORATION OF MARKET PLAYERS 5 MARKET FACTOR ANALYSIS 5.1 VALUE CHAIN 5.1.1 R&D 5.1.2 MANUFACTURING 5.1.3 DISTRIBUTION AND SALES 5.1.4 POST-SALES MONITORING 5.2 PORTER’S FIVE FORCES MODEL 5.2.1 BARGAINING POWER OF SUPPLIERS 5.2.2 BARGAINING POWER OF BUYERS 5.2.3 THREAT OF NEW ENTRANTS 5.2.4 THREAT OF SUBSTITUTES 5.2.5 INTENSITY OF RIVALRY 5.3 COVID-19 IMPACT ANALYSIS 5.3.1 OVERVIEW 5.3.2 IMPACT ON MARKET GROWTH 5.3.3 IMPACT ON THE COUNTRY 5.3.4 IMPACT ON MAJOR PLAYERS 6 UK DRY EYE MARKET, BY PRODUCT 6.1 OVERVIEW 7 UK DRY EYE MARKET, BY DRUGS 7.1 OVERVIEW 8 UK DRY EYE MARKET, BY DISTRIBUTION CHANNEL 8.1 OVERVIEW 9 COMPETITIVE LANDSCAPE 9.1 OVERVIEW 9.2 COMPETITIVE BENCHMARKING 9.3 UK DRY EYE MARKET: COMPANY RANKING 9.4 LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS 9.5 KEY DEVELOPMENTS & GROWTH STRATEGIES 9.5.1 NEW PRODUCT LAUNCHES 9.5.2 ACQUISITIONS 9.6 FINANCIAL MATRIX 10 COMPANY PROFILES 10.1 OTSUKA PHARMACEUTICAL CO., LTD 10.1.1 COMPANY OVERVIEW 10.1.2 FINANCIAL OVERVIEW 10.1.3 PRODUCTS/SERVICES OFFERED 10.1.4 KEY DEVELOPMENTS 10.1.5 SWOT ANALYSIS 10.1.6 KEY STRATEGIES 10.2 SANTEN PHARMACEUTICAL CO., LTD 10.2.1 COMPANY OVERVIEW 10.2.2 FINANCIAL OVERVIEW 10.2.3 PRODUCTS/SERVICES OFFERED 10.2.4 KEY DEVELOPMENTS 10.2.5 SWOT ANALYSIS 10.2.6 KEY STRATEGIES 10.3 BAUSCH AND LOMB PVT LTD 10.3.1 COMPANY OVERVIEW 10.3.2 FINANCIAL OVERVIEW 10.3.3 PRODUCTS/SERVICES OFFERED 10.3.4 KEY DEVELOPMENTS 10.3.5 SWOT ANALYSIS 10.3.6 KEY STRATEGIES 10.4 ALLERGAN PLC 10.4.1 COMPANY OVERVIEW 10.4.2 FINANCIAL OVERVIEW 10.4.3 PRODUCTS/SERVICES OFFERED 10.4.4 KEY DEVELOPMENTS 10.4.5 SWOT ANALYSIS 10.4.6 KEY STRATEGIES 10.5 TEVA PHARMACEUTICAL INDUSTRIES LTD 10.5.1 COMPANY OVERVIEW 10.5.2 FINANCIAL OVERVIEW 10.5.3 PRODUCTS/SERVICES OFFERED 10.5.4 KEY DEVELOPMENTS 10.5.5 SWOT ANALYSIS 10.5.6 KEY STRATEGIES 10.6 JOHNSON & JOHNSON SERVICES INC. 10.6.1 COMPANY OVERVIEW 10.6.2 FINANCIAL OVERVIEW 10.6.3 PRODUCTS/SERVICES OFFERED 10.6.4 KEY DEVELOPMENTS 10.6.5 SWOT ANALYSIS 10.6.6 KEY STRATEGIES 10.7 NOVARTIS AG 10.7.1 COMPANY OVERVIEW 10.7.2 FINANCIAL OVERVIEW 10.7.3 PRODUCTS/SERVICES OFFERED 10.7.4 KEY DEVELOPMENTS 10.7.5 SWOT ANALYSIS 10.7.6 KEY STRATEGIES 10.8 I-MED PHARMA INC 10.8.1 COMPANY OVERVIEW 10.8.2 FINANCIAL OVERVIEW 10.8.3 PRODUCTS/SERVICES OFFERED 10.8.4 KEY DEVELOPMENTS 10.8.5 SWOT ANALYSIS 10.8.6 KEY STRATEGIES 10.9 LENSTORE 10.9.1 COMPANY OVERVIEW 10.9.2 FINANCIAL OVERVIEW 10.9.3 PRODUCTS/SERVICES OFFERED 10.9.4 KEY DEVELOPMENTS 10.9.5 SWOT ANALYSIS 10.9.6 KEY STRATEGIES 10.10 VISION DIRECT 10.10.1 COMPANY OVERVIEW 10.10.2 FINANCIAL OVERVIEW 10.10.3 PRODUCTS/SERVICES OFFERED 10.10.4 KEY DEVELOPMENTS 10.10.5 SWOT ANALYSIS 10.10.6 KEY STRATEGIES 11 APPENDIX 11.1 REFERENCES 11.2 RELATED REPORTS

Companies Mentioned

Otsuka pharmaceutical Co Ltd, Teva Pharmaceutical Industries Ltd, Johnson & Johnson Services Inc, Novartis AG, I-MED Pharma, Lenstore, and Vision Direct

Reviews

There are no reviews yet.

Be the first to review “UK Dry Eye Market Report Forecast till 2027”

Related products